He & She MD Review

The privacy notice identifies NextGen Telehealth Inc. DBA He & She MD at a Newport Beach address. He & She MD functions as the consumer-facing platform, while a separate professional entity is responsible for medical care and an independent pharmacy dispenses any prescription.

The current homepage names Wasef Health, PC, care of Michael Wasef, MD, as the clinical provider organization. Terms last revised January 11, 2022 instead repeatedly name Beluga Health, P.A. and incorporate Bask Health platform terms. The review does not assume which relationship governs every current service.

The homepage names Specialty Medical Drugstore LLC, doing business as GoGoMeds, and F&F Pharmacies Inc., doing business as Jungle Jim's Pharmacy. The assigned pharmacy for a given prescription is not identified before evaluation, and current pages do not publish the exact compound formula or label for most products.

The current flow starts with a provider-stated five-minute medical questionnaire. A licensed U.S. clinician reviews the information and may prescribe only when appropriate. Current pages advertise secure messaging, dose adjustments when appropriate, and delivery after approval.

The treatment catalog is broad, but this review does not convert every page title into a therapy. It consolidates by active ingredient and route and leaves incomplete combinations and branded programs in the narrative. This prevents a benefit label such as Daily ED Support from masquerading as a specific medication.

Compounded semaglutide injection product-page rates are $99 per month for twelve months, $199 for six, $219 for three, and $249 for one. Their unweighted mean is $191.50, displayed as Avg. $192/mo. Compounded tirzepatide rates are $159, $289, $309, and $339, averaging $274.

A separate weight-loss plans page promotes semaglutide at $139 per month and tirzepatide at $199 per month for a six-month term. Homepage footnotes say those first six-month terms renew at $199 and $289 per month. Promotional first-cycle prices are not used in the standard-card averages.

Oral semaglutide is listed at $209, $239, $259, or $279 per month, averaging $246.50 and displayed as Avg. $247/mo. Exact strength, quantity, compounding formula, and food-related administration conditions are not published, so it remains outside like-for-like comparison.

Oral tirzepatide is listed at $269, $289, $309, or $339 per month. The page calls it a daily tablet but incorrectly labels its table Sermorelin Injectable Pricing. Tirzepatide has no FDA-approved oral dosage form, and the provider does not disclose enough formula detail for a reusable card, so the offer remains editorial-only.

Sermorelin's standard page lists $149, $159, $179, or $229 per month, averaging $179. A separate landing page promotes a three-month package with $99 for the first month and $149 for the next two, totaling $397. That introduction is kept separate from the standard average.

NAD+ injection and nasal spray pages each list $149, $159, $179, or $229 per month, averaging $179. A dedicated 1,000 mg NAD+ landing page instead shows $139 for an annual term. The card preserves both statements, combines the two routes under one ingredient, and disables comparison.

Glutathione injection is $100 per month for three months or $125 for one, averaging $112.50 and displayed as Avg. $113/mo. The exact strength, vial quantity, source ingredient, and dispensing pharmacy are not public. FDA has warned compounders about using unsuitable ingredients in sterile glutathione products.

The site also has glutathione cream, NAD cream, lipotropic+B12, and MOTS-C pages. Glutathione cream copy tells the reader to inject it, the NAD cream page was not reliably accessible, and lipotropic+B12 is a multi-ingredient formula. None becomes a separate normalized medication card.

MOTS-C is advertised at $149 per month for a six-month plan. Current FDA briefing material says MOTS-C is not a component of an approved drug, human-use evidence is lacking, and immunogenicity and other safety risks remain unknown. The provider's page is recorded, but MOTS-C remains editorial-only.

Enclomiphene is listed at $139, $149, $169, or $189 per month, averaging $161.50 and displayed as Avg. $162/mo. The page calls treatment lab guided, but exact strength, quantity, compounding status, required panels, test costs, and monitoring cadence are not public.

Current pages advertise testosterone injection, gel, and tablet at $119, $139, $159, or $179 per month. The 2022 terms state that the program is not appropriate for TRT and that participating providers cannot prescribe TRT by telehealth. Testosterone stays outside normalized cards until He & She MD publishes current terms that resolve the contradiction.

Estradiol patch, gel, and tablet pages use one quarterly schedule: $125 per month, charged as $375 every three months. The review consolidates those route choices into one card. Progesterone is not sold as a standalone program and is included without an added charge only when prescribed with estradiol purchased through the platform.

The sexual-health catalog uses the labels On-Demand ED, Daily ED Support, ED Combination Therapy, and Duration & Control. Public pages show per-dose or per-day ranges but do not disclose exact ingredients and quantities for each selection. The homepage mentions sildenafil and tadalafil generally, which is not enough to map every branded program.

Men's and women's hair pages describe oral, topical, and combination programs involving minoxidil, finasteride, dutasteride, tretinoin, biotin, or patient-specific combinations. A shared $79 starting headline does not establish a like-for-like quantity or formula, so these remain editorial-only.

Current product pages say treatment prices include medication when prescribed, supplies, shipping, and provider support, without a separate membership fee. The weight-loss plans page says a non-candidate is not charged. It remains necessary to confirm whether every longer term is collected fully upfront and what renewal follows it.

The 2022 terms describe a different membership model. They refer to 28-to-30-day recurring charges, a nonrefundable initial fee, separate diagnosis and Quest laboratory charges, up to eight consults and home blood draws, and a customer-service phone placeholder that was never filled. Those provisions cannot be silently applied to the newer product plans.

Current pages do not reconcile an operative cancellation deadline, current-cycle refund eligibility, multi-month early termination, or the amount and timing of post-term renewals. Before paying, a buyer should capture the final total, billing cadence, cancellation control, refund rule, and renewal amount shown at checkout.

State coverage is contradictory. The homepage says GLP-1 medication ships everywhere except Louisiana and longevity and HRT ship nationwide. The shipping policy says shipping is limited to 47 continental states and separately excludes New Jersey, Mississippi, Alaska, Hawaii, and Guam.

The homepage says Jungle Jim's Pharmacy cannot dispense sterile compounds and lacks licenses in California, Nevada, New Jersey, North Carolina, Texas, Massachusetts, Mississippi, New Hampshire, West Virginia, and Delaware. Which partner fills sterile products or excluded destinations is not explained on the public pages.

The shipping policy says approved medication uses FedEx or UPS, includes tracking, arrives in discreet packaging, and typically takes three to five business days. Other pages say expedited delivery, two to three days, or one to two days. These are provider estimates rather than one reliable guarantee.

General support is available at support@heandshemd.com, and the contact page lists staffed hours Monday through Friday from 9 a.m. to 6 p.m. Eastern. Product pages' 24/7 wording is best read as secure-messaging access, not proof of round-the-clock staffed customer support or a response-time commitment.

The privacy policy describes information sharing with clinicians, pharmacies, service providers, analytics vendors, and advertising partners. It says online identifiers used for interest-based advertising may count as a sale under California's broad definition. Its appended HIPAA notice still contains an unresolved effective-date placeholder.

The posted telehealth-consent page displays an error instead of its incorporated PDF. Other template problems include an Effecty name on NAD+ pages, injectable headings on oral pages, transdermal copy on a tablet page, injectable directions on a cream page, and repeated weight-loss testimonials on unrelated treatment pages.

FDA says compounded semaglutide and tirzepatide are not FDA approved and do not receive premarket review for safety, effectiveness, or quality. FDA also describes dosing, titration, storage, labeling, and salt-form concerns. The dispensing label should be checked for active ingredient, concentration, additives, instructions, and pharmacy.

The site's phrase FDA-regulated pharmacies is not independent proof of product approval or pharmacy quality. FDA states that establishment registration and drug listing do not denote approval or verification. State pharmacy licensure, the applicable federal compounding pathway, and product-specific quality controls are separate questions.

The strongest features are public standard price schedules, several term choices, a wide in-scope catalog, a simple online flow, named partners, free delivery, and secure follow-up. The main limitations are stale and conflicting legal documents, unclear cancellation and refund rules, inconsistent availability, weak formulation detail, and repeated content errors.